Canopy Growth Corporation

CGC Healthcare Drug Manufacturers Specialty & Generic

Canopy Growth Corporation’s revenue for fiscal 2026 (year ended March 2026) was $206.0 million, up 6.55% from fiscal 2025. In the quarter to June 2026, revenue grew 12.4%, EPS grew 87.5%, free cash flow fell 117.6% and total debt fell 18.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, operating cash flow growth for three.

0.71 0.03 −4.05%
Market cap
$311.2M
P/E
0.0×
Fwd P/E
−5.6×
Dividend yield
—
F-score
5/9
Altman Z
−13.21
Beneish M
−3.49
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
2.01 1.98 1.37 1.89
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(30.58) (32.50) (20.96) (22.21)
P/B ratio
0.75 0.72 0.56 0.81
EV/Sales
1.73 1.44 0.90 1.54
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(5.09) (4.56) (3.65) (5.40)
Current Ratio
5.50 5.34 3.34 3.04
Net Debt/EBITDA
9.92 8.57 1.57 8.40
Debt/Equity
0.31 0.30 0.33 0.35
Earnings Yield
(133.86%) (113.54%) (61.51%) (46.77%)
Free Cash Flow Yield
(16.94%) (15.95%) (17.83%) (15.12%)
Free Cash Flow per Share
(0.05) (0.04) (0.05) (0.04)
Book value per Share
1.95 1.57 1.69 1.18
Free Cash Flow
(14.15) (13.45) (14.34) (18.60)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates